Page last updated: 2024-12-09
map4
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
MAP4: partial amino acid sequence given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 1795545 |
| CHEMBL ID | 1488784 |
| SCHEMBL ID | 179781 |
| MeSH ID | M0189695 |
Synonyms (21)
| Synonym |
|---|
| gtpl1414 |
| NCGC00024744-01 |
| tocris-0711 |
| map4 |
| NCGC00024744-02 |
| (2s)-2-amino-2-methyl-4-phosphonobutanoic acid |
| AKOS006272533 |
| (s)-2-amino-2-methyl-4-phosphonobutanoic acid |
| 157381-42-5 |
| CHEMBL1488784 |
| SCHEMBL179781 |
| sr-01000597625 |
| SR-01000597625-1 |
| J-009412 |
| 4-phosphono-l-isovaline |
| DTXSID40935660 |
| Q27083516 |
| (s)-map4 |
| l-isovaline, 4-phosphono- |
| CS-0020934 |
| HY-101164 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Protein Targets (3)
Potency Measurements
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Microtubule-associated protein tau | Homo sapiens (human) | Potency | 14.1254 | 0.1800 | 13.5574 | 39.8107 | AID1468 |
| aldehyde dehydrogenase 1 family, member A1 | Homo sapiens (human) | Potency | 39.8107 | 0.0112 | 12.4002 | 100.0000 | AID1030 |
| histone acetyltransferase KAT2A isoform 1 | Homo sapiens (human) | Potency | 35.4813 | 0.2512 | 15.8432 | 39.8107 | AID504327 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Bioassays (7)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1347154 | Primary screen GU AMC qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1508630 | Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay | 2021 | Cell reports, 04-27, Volume: 35, Issue:4 | A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome. |
| AID1346255 | Rat mGlu6 receptor (Metabotropic glutamate receptors) | 2002 | Current drug targets. CNS and neurological disorders, Jun, Volume: 1, Issue:3 | The metabotropic glutamate receptors: structure, activation mechanism and pharmacology. |
| AID1346251 | Rat mGlu8 receptor (Metabotropic glutamate receptors) | 1997 | Molecular pharmacology, Jan, Volume: 51, Issue:1 | Cloning and expression of rat metabotropic glutamate receptor 8 reveals a distinct pharmacological profile. |
| AID1346251 | Rat mGlu8 receptor (Metabotropic glutamate receptors) | 2000 | Brain research. Molecular brain research, Mar-10, Volume: 76, Issue:1 | Constraints on proper folding of the amino terminal domains of group III metabotropic glutamate receptors. |
| AID1346283 | Rat mGlu4 receptor (Metabotropic glutamate receptors) | 1999 | The Journal of biological chemistry, Apr-09, Volume: 274, Issue:15 | Ligand binding to the amino-terminal domain of the mGluR4 subtype of metabotropic glutamate receptor. |
| AID1346263 | Human mGlu7 receptor (Metabotropic glutamate receptors) | 2000 | Naunyn-Schmiedeberg's archives of pharmacology, Dec, Volume: 362, Issue:6 | Binding of [3H](2S,1'S,2'S)-2-(9-xanthylmethyl)-2-(2'-carboxycyclopropyl) glycine ([3H]LY341495) to cell membranes expressing recombinant human group III metabotropic glutamate receptor subtypes. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (7)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (28.57) | 18.2507 |
| 2000's | 3 (42.86) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (28.57) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 56.20
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.
| This Compound (56.20) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 1 (14.29%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (85.71%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||